Pyoderma gangrenosum
Tha Pyoderma gangrenosum na ghalar craiceann tearc, inflammatory far a bheil pustules no nodules goirt a’ fàs ulcers a bhios a’ fàs mean air mhean. Chan eil pyoderma gangrenosum gabhaltach. Faodaidh làimhseachadh a bhith a’ toirt a-steach corticosteroids, ciclosporin, no diofar antibodies monoclonal. Ged a dh’ fhaodadh e buaidh a thoirt air daoine aig aois sam bith, bidh e a’ toirt buaidh sa mhòr-chuid air daoine sna 40an is 50an aca.
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Air cas neach le colitis ulcerative.
References
Is e suidheachadh craiceann tearc a th’ ann an Pyoderma gangrenosum a dh’ adhbhraicheas ulcers goirt le oirean dearg no purpaidh. Tha e air a chomharrachadh mar ghalar sèid agus tha e na phàirt de bhuidheann ris an canar dermatoses neutrophilic. Tha adhbhar pyoderma gangrenosum iom-fhillte, a’ toirt a-steach duilgheadasan le dìonachd dhùthchasach agus atharrachail ann an daoine a tha dualtach gu ginteil. O chionn ghoirid, tha luchd-rannsachaidh air fòcas a chuir air follicule fuilt mar thoiseach tòiseachaidh a’ ghalair.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Is e suidheachadh craiceann ainneamh a th’ ann an Pyoderma gangrenosum a dh’ adhbhraicheas ulcers gu math goirt. Ged nach eil sinn gu tur a’ tuigsinn a adhbhar, tha fios againn gu bheil e a’ toirt a-steach barrachd gnìomhachd cuid de cheallan dìon. Chan eil làimhseachadh an galair fhathast furasta. Tha diofar dhrogaichean againn a chuireas stad air an t-siostam dìon no a dh’ atharrachadh a ghnìomhachd. Còmhla riutha sin, bidh sinn cuideachd a 'cuimseachadh air a bhith a' làimhseachadh lotan agus a 'stiùireadh pian. Is e corticosteroids agus cyclosporine gu tric a’ chiad roghainn airson làimhseachadh, ach o chionn ghoirid, chaidh barrachd rannsachaidh a dhèanamh air a bhith a’ cleachdadh leigheasan bith-eòlais leithid luchd-bacadh TNF-α. Tha na bith-eòlasan sin a’ sìor fhàs nas fheàrr, gu sònraichte ann an euslaintich le suidheachaidhean sèid eile, agus thathas gan cleachdadh nas tràithe ann am pròiseas galair.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
